Business
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"Conference Call at 4:30 pm ET Today\nBURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2021 and provided a corporate update. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We made significant progress in 2021, marked by the positive read-out of strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial, which represented a transformative event for Xenon. We have successfully carried this positive momentum into 2022 as we look forward to an end-of-Phase 2 meeting with the FDA in the second quarter and continue to focus on initiation of Phase 3 development for XEN1101 in the second half of 2022. In addition, we have now filed an IND with the FDA to support the initiation of our company-sponsored Phase 2 XEN1101 clinical trial in major depressive disorder, anticipated to commence in the first half of this year.” Mr. Mortimer added, “Patient enrollment is ongoing in our pediatric XEN496 Phase 3 ‘EPIK’ clinical trial, which is expected to be completed in the first half of 2023. Our partnered programs also continue to advance through development with two separate Phase 2 clinical trials underway from Neurocrine Biosciences in adult patients with focal-onset seizures and pediatric patients with SCN8A-related epilepsy.” Highlights and Anticipated Milestones Proprietary Programs XEN1101XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). In October 2021, Xenon announced positive results from its Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety and tolerability of XEN1101 administered as an adjunctive treatment for adult patients with focal epilepsy. The topline data showed all primary and secondary seizure reduction endpoints were statistically significant across all dose groups, including the primary endpoint of median reduction from baseline in monthly seizure frequency and in the key secondary endpoint of patients with at least a 50% reduction in monthly focal seizure frequency from baseline, with p-values of","length":2722,"tagName":"div"}]